Walk down any supplement aisle this year and you’ll spot a pattern. Protein bars with bigger numbers on the front. Collagen powders promising firmer skin and stronger muscles. Quiet little hints aimed at people on weight-loss injections. The common thread is GLP-1 medications, the drug class that includes semaglutide, which has changed what millions of people eat, buy and worry about.
The worry tends to be the same one. When appetite drops and the scale moves fast, what exactly is leaving the body? Fat only, or muscle and facial fullness too? Collagen peptides have stepped into that gap with a pitch that sounds almost too tidy.
So what does the research say? I went through five recent studies, from a 68-week semaglutide trial to a 2026 analysis of Danish grocery receipts, to separate real shifts from marketing gloss. Here are seven ways these two trends are colliding, and where the science is still thin.
Grocery Baskets Are Shrinking and Getting Denser
Danish researchers tracked supermarket receipts from 293 people who started a GLP-1 medication and 884 matched comparisons. In the year after their first prescription, the starters spent about 35,000 kroner on food, down from roughly 52,500 the year before. That’s a drop of about a third.
What landed in the cart changed, too. Calories per 100 grams slipped, sugar fell, and protein edged up from 6.6 to 6.9 grams per 100 grams, with a shift away from ultra-processed foods. Small numbers? Yes. The authors say so themselves, and they flag a self-selected sample and no BMI data. Still, for anyone selling food or supplements, the message is blunt: smaller baskets mean every item has to earn its place.
Think about what that means at the kitchen table. Someone eating less can’t count on a big plate to cover their protein and micronutrients, so nutrient density, not volume, becomes the selling point. That’s a plausible read, not a proven one. Receipts show what people bought, not what they ate or how they felt afterward.
The Scale Stopped Being the Only Scoreboard
The landmark STEP 1 trial enrolled 1,961 adults without diabetes. After 68 weeks on weekly semaglutide, participants lost 14.9% of their body weight on average, versus 2.4% on placebo. Impressive. But people no longer ask only “how much?” They ask “what kind of weight?”
In the trial’s body-composition analysis, fat mass dropped more than lean mass did. That’s reassuring, though lean tissue wasn’t spared entirely, and a 2025 review notes that evidence on GLP-1 therapy and muscle loss is mixed. When a headline number that big comes with a question mark about muscle, a whole shelf of products shows up to answer it.
Here’s the practical takeaway. Ask whether your care team tracks anything beyond the number on the scale. Strength, function and body composition tell a fuller story. In STEP 1, participants on semaglutide also reported bigger improvements in physical functioning than those on placebo, which hints that losing fat and feeling capable can go together.
Collagen Peptides Became a Muscle Conversation
A 2024 meta-analysis in Sports Medicine pooled 19 trials with 768 healthy adults who took collagen peptides while training. Fat-free mass improved (standardized mean difference 0.48), while strength gains were smaller (0.19). Certainty of evidence was moderate for body composition and low or very low for most other outcomes. The authors’ read of the data: roughly 15 grams a day for at least eight weeks.
Here’s the catch, and I’d tape it to every collagen tub. These participants were training. Collagen was an add-on to exercise, not a replacement for it. And I found no trial testing collagen in people taking GLP-1 medications. The market is borrowing muscle data from gym-goers and lending it to a different group. It was already a sizable business, too: the paper puts global collagen peptide sales around $599 million in 2020. For readers comparing where collagen peptide products are sold, Peptides Costa Rica online is one regional example of the expanding market—but the same caution applies: product availability is not evidence of benefit in GLP-1 users.
One more detail worth knowing. The strongest signal in that analysis wasn’t muscle at all. Tendon structure showed the largest effect (0.67), but the certainty there was very low. Interesting for athletes, thin for anyone shopping for muscle protection on a GLP-1.
“Ozempic Face” Pulled Skin Into the Spotlight
Few side-effect nicknames have traveled as fast. A 2025 review in Endocrine reports that many patients on GLP-1 therapy notice facial aging, and that it isn’t tied to one drug alone. Rapid fat loss changes the proportions of the face, and that reads as older.
The review also lays out two competing stories. GLP-1 drugs may affect skin-supporting cells in ways that speed aging, yet they may also lower inflammation and the glycation products that stiffen collagen. Which effect wins? The authors say the mechanisms still need sorting out. That honesty matters, because “fix the face” is a very attractive marketing promise.
If facial changes worry you, bring it up with your prescriber early rather than after the fact. The pace of weight loss is one of the few levers a care team can actually discuss with you, and it’s far easier to adjust the plan than to chase a result once it’s already visible.
Beauty-From-Within Found a Motivated Audience
Oral collagen already had a skin story. A 2023 meta-analysis in Nutrients pooled 26 randomized trials with 1,721 participants and found that hydrolyzed collagen improved skin hydration and elasticity compared with placebo. Trials ran anywhere from 2 to 12 weeks.
Now picture someone worried about a changing face reading that result. You can see why the pitch lands. But look at what was measured: hydration and elasticity. Not volume. The authors also flagged biases in the included trials and called for larger studies. So collagen may nudge skin quality, but it isn’t a stand-in for the fat pads that shrink during rapid weight loss, and I found no research showing otherwise.
Trial length matters here too. A 12-week result says little about someone who stays on a medication for years, and nobody has shown how those two timelines interact. Early data can be promising and still leave the practical question open.
Smaller Appetites Raise the Stakes on Nutrition Quality
Eating less is the point of these medications. It also leaves less room for error. The Endocrine review ties facial aging to rapid weight loss and malnutrition, and notes similar skin changes in people after bariatric surgery. In STEP 1, nausea and diarrhea were the most common side effects, and stomach-related problems led 4.5% of semaglutide users to quit versus 0.8% on placebo. Tolerability shapes what people can actually eat.
The Danish receipts hint at scale: spending fell by about a third. Spending isn’t intake, so don’t over-read it, but the direction is clear. With fewer meals to work with, protein quality matters. Collagen lacks tryptophan, an essential amino acid, so it can’t be your only protein source. A registered dietitian can help you build the rest of the plate. Think of collagen as a side dish, not the main course.
Marketing Is Running Ahead of the Evidence
Here’s the part I’d flag for anyone holding a collagen tub next to a GLP-1 prescription. The studies are real, but they answer different questions. The table sorts what’s solid from what’s inference.
| Claim you’ll hear | What the research shows | How much to trust it |
| Collagen plus training builds lean mass | 19-trial meta-analysis: fat-free mass gain (SMD 0.48) | Moderate certainty; healthy adults, not GLP-1 users |
| Collagen boosts strength | Smaller effect (SMD 0.19) | Low certainty |
| Collagen improves skin | 26 RCTs: better hydration and elasticity | Short trials (2–12 weeks); bias concerns |
| Semaglutide drives weight loss | −14.9% vs −2.4% over 68 weeks | Large RCT; GI side effects led more people to stop |
| GLP-1 users shop differently | Fewer calories and sugar, slightly more protein | Small, self-selected Danish sample |
| Collagen prevents “Ozempic face” or GLP-1 muscle loss | I found no direct trials | Unproven |
Read that last row twice. No direct trial links collagen to protecting muscle or facial volume during GLP-1 treatment, at least none I could find. That doesn’t mean it can’t help. It means the claim is a hypothesis dressed up as a result. Ask your prescriber or a registered dietitian before adding supplements, especially if you have other health conditions or take other medications.
The Bottom Line
If you’re taking a GLP-1 medication and eyeing collagen, start with the boring stuff. Ask your prescriber what protein target fits you, add resistance training if your clinician approves, and build meals around complete proteins. Then, if you still want collagen, treat it as an optional extra with modest, exercise-linked evidence, and check what dose the studies actually used instead of trusting a slogan. The market will keep moving fast. Your decisions can move slower. The study to watch for is a randomized trial that pairs collagen with GLP-1 treatment and resistance training, because that’s the question shoppers are really asking, and nobody has answered it yet. Until then, a little healthy skepticism costs you nothing. This article is for information and isn’t medical advice.
Read next: 6 Best Sites to Compare Online GLP-1 Weight-Loss Programs in 2026
References for further reading:
Bischof, K., Moitzi, A. M., Stafilidis, S., & König, D. (2024). Impact of collagen peptide supplementation in combination with long-term physical training on strength, musculotendinous remodeling, functional recovery, and body composition in healthy adults: A systematic review with meta-analysis. Sports Medicine, 54(11), 2865–2888. https://doi.org/10.1007/s40279-024-02079-0
Paschou, I. A., Sali, E., Paschou, S. A., Tsamis, K. I., Peppa, M., Psaltopoulou, T., Nicolaidou, E., & Stratigos, A. J. (2025). GLP-1RA and the possible skin aging. Endocrine, 89(3), 680–685. https://doi.org/10.1007/s12020-025-04293-w
Pu, S.-Y., Huang, Y.-L., Pu, C.-M., Kang, Y.-N., Hoang, K. D., Chen, K.-H., & Chen, C. (2023). Effects of oral collagen for skin anti-aging: A systematic review and meta-analysis. Nutrients, 15(9), 2080. https://doi.org/10.3390/nu15092080
Sørensen, K. K., Møller, F. T., Yazdanfard, P. D. W., Hasselbalch, R., Kragholm, K. H., Andersen, M. P., & Torp-Pedersen, C. (2026). Consumer food purchases after glucagon-like peptide-1 receptor agonist initiation. JAMA Network Open, 9(1), e2555449. https://doi.org/10.1001/jamanetworkopen.2025.55449
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183